This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Top 5 High-Flying Mid-Cap Stocks Despite a Volatile August
by Nalak Das
We have narrowed our search to five mid-cap stocks that have provided double-digit returns in the past month. These are: FN, FRSH, HRB, EXEL, PSN.
HRBNegative Net Change EXELPositive Net Change FNPositive Net Change FRSHNegative Net Change PSNPositive Net Change
biotechnology business-services consumer-discretionary internet tech-stocks
Esperion (ESPR) Aims to Expand Key Drug Labels for Growth
by Zacks Equity Research
Esperion's (ESPR) non-statin approved drugs uptake has continued to be the growth driver since launch. However, the company is currently facing a conflict with its partner, Daiichi Sankyo, regarding milestone payments.
CORTPositive Net Change ANIPPositive Net Change ESPRPositive Net Change ANVSPositive Net Change
biotechnology medical
Novartis' (NVS) Sandoz Gets FDA Nod for Tysabri's Biosimilar
by Zacks Equity Research
Novartis' (NVS) generic division, Sandoz, wins FDA approval for a biosimilar of the leading MS drug Tysabri.
NVSPositive Net Change BIIBPositive Net Change DVAXPositive Net Change SPRONo Net Change
biotechnology pharmaceuticals
Exelixis (EXEL) Late-Stage Study in Pancreatic Tumors Positive
by Zacks Equity Research
Exelixis' (EXEL) phase III CABINET study shows dramatic improvement in efficacy in advanced pancreatic neuroendocrine tumors and advanced extra-pancreatic neuroendocrine tumors.
BMYPositive Net Change DVAXPositive Net Change EXELPositive Net Change SPRONo Net Change
biotechnology pharmaceuticals
Gilead (GILD) Gets FDA Nod for Veklury for Hepatic Impairment
by Zacks Equity Research
Gilead's (GILD) anti-viral treatment Veklury gets FDA approval for the treatment of COVID-19 in patients with mild, moderate or severe hepatic impairment.
GSKPositive Net Change DVAXPositive Net Change GILDPositive Net Change SPRONo Net Change
biotechnology pharmaceuticals
Here's Why You Should Add Corcept (CORT) Stock to Your Portfolio
by Zacks Equity Research
Corcept (CORT), a top-ranked stock, is witnessing incremental sales in its only marketed product, Korlym. It is also making good progress with its promising set of pipeline candidates.
MRKNegative Net Change CORTPositive Net Change ANIPPositive Net Change ANVSPositive Net Change
biotechnology medical
Bionomics (BNOX) Up on Positive Updates on PTSD & SAD Candidate
by Zacks Equity Research
Bionomics (BNOX) gains as it provides updates on further development of its lead pipeline candidate, BNC210, developed for post-traumatic stress disorder and social anxiety disorder.
CORTPositive Net Change ANIPPositive Net Change ANVSPositive Net Change
biotechnology medical
Biotech Stock Roundup: REGN Up on Approval, APLS, NVAX Gain on Updates & More
by Zacks Equity Research
Regulatory updates from Regeneron (REGN) and Apellis (APLS) are in focus in the biotech sector.
REGNPositive Net Change GILDPositive Net Change NVAXNegative Net Change APLSPositive Net Change FULCPositive Net Change
biotechnology biotechs pharmaceuticals
Barings BDC (BBDC)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
BBDCPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Fulcrum (FULC) Up as FDA Lifts Clinical Hold on SCD Candidate
by Zacks Equity Research
Fulcrum's (FULC) shares surge as the FDA lifts the clinical hold it had earlier placed on its pipeline candidate FTX-6058, to treat patients with sickle cell disease.
CORTPositive Net Change ANIPPositive Net Change FULCPositive Net Change ANVSPositive Net Change
biotechnology medical
Bristol Myers' (BMY) Opdivo Gets EC Nod for Label Expansion
by Zacks Equity Research
Bristol Myers (BMY) obtains approval in the EU for Opdivo for the adjuvant treatment of adults and adolescents with stage IIB or IIC melanoma who have undergone complete resection.
BMYPositive Net Change DVAXPositive Net Change SPRONo Net Change
biotechnology biotechs
Apellis (APLS) Updates on Safety Concerns for Syfovre
by Zacks Equity Research
Apellis' (APLS) shares rise as the company provides updates on safety concerns regarding Syfovre, approved for the treatment of geographic atrophy.
EBSNegative Net Change CORTPositive Net Change APLSPositive Net Change ANVSPositive Net Change
biotechnology medical
Upwork (UPWK) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
UPWKPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy Granite Ridge Resources, Inc. (GRNT) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
GRNTNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Perdoceo Education (PRDO)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
PRDONegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Gilead's (GILD) Leukemia Study Progress Put on Clinical Hold
by Zacks Equity Research
Gilead (GILD) faces a setback as the FDA puts a partial clinical hold on enrolling new patients in studies evaluating magrolimab for treating AML in the United States.
DVAXPositive Net Change GILDPositive Net Change SPRONo Net Change ACLXPositive Net Change
biotechnology biotechs pharmaceuticals
Timber (TMBR) to Get Acquired by LEO Pharma for $36M, Stock Up
by Zacks Equity Research
Timber (TMBR) surges as LEO Pharma offers to acquire it for approximately $36 million.
EBSNegative Net Change CORTPositive Net Change ANVSPositive Net Change
biotechnology medical
Anebulo (ANEB) Gains on Positive FDA Response for ANEB-001
by Zacks Equity Research
Anebulo (ANEB) gains on positive FDA response for the phase III development of its lead candidate ANEB-001 for treating patients with acute cannabinoid intoxication.
EBSNegative Net Change CORTPositive Net Change ANVSPositive Net Change ANEBPositive Net Change
biotechnology medical
Calliditas (CALT) Up as sNDA for Tarpeyo Gets Priority Review
by Zacks Equity Research
Calliditas (CALT) soars as the supplement new drug application seeking to convert accelerated approval of Tarpeyo delayed-release capsule to full approval gets accepted by the FDA.
EBSNegative Net Change CORTPositive Net Change ANVSPositive Net Change
biotechnology medical
Regeneron (REGN) Gets FDA Nod for Higher Dose of Eylea
by Zacks Equity Research
Regeneron (REGN) obtains FDA approval for a higher dose of aflibercept injection under the brand name Eylea HD for various ophthalmology indications. The regulatory body also approves Veopoz.
REGNPositive Net Change SNYPositive Net Change ALNYPositive Net Change BAYRYPositive Net Change
biotechnology biotechs pharmaceuticals
Exelixis' (EXEL) Prostate Cancer Study Meets Primary Endpoint
by Zacks Equity Research
Exelixis (EXEL) and partner Ipsen's phase III CONTACT-02 study meets one of the two primary endpoints in prostate cancer patients.
RHHBYPositive Net Change BMYPositive Net Change EXELPositive Net Change
biotechnology biotechs pharmaceuticals
Regeneron's (REGN) Application for Blood Cancer Drug Accepted
by Zacks Equity Research
Regeneron's (REGN) application seeking approval of odronextamab for patients with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma gets accepted for review in the EU.
REGNPositive Net Change SNYPositive Net Change DVAXPositive Net Change SPRONo Net Change
biotechnology biotechs pharmaceuticals
Pieris (PIRS) Up On Receiving Milestone Payment From Partner
by Zacks Equity Research
Pieris (PIRS) soars as partner Boston Pharmaceuticals initiated early-stage study of PRS-342/BOS-342, triggering an undisclosed milestone payment to the former.
EBSNegative Net Change CORTPositive Net Change PIRSPositive Net Change ANVSPositive Net Change
biotechnology medical
Solaris Oilfield Infrastructure, Inc. (SOI)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
SOIPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
bluebird's (BLUE) Lovo-cel to Not Face Advisory Committee
by Zacks Equity Research
bluebird (BLUE) announces that its gene therapy, lovotibeglogene autotemcel, developed for sickle cell disease, will not be scheduled for advisory committee meeting, thereby accelerating the path for approval.
VRTXNegative Net Change CORTPositive Net Change CRSPPositive Net Change
biotechnology medical